Methadone: A review of drug-drug and pathophysiological interactions

Critical Reviews in Clinical Laboratory Sciences

Volumn 48, Issue 4, 2011, Pages 171-195

  Kapur, Bhushan M ^a,b,c   Hutson, Janine R ^b,c   Chibber, Tamanna ^a   Luk, Adriana ^a   Selby, Peter ^d,e  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

1 acid glycoprotein; CYP P450; drug interactions; Methadone; pathophysiological factors

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMPRENAVIR; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; COCAINE; DELAVIRDINE; EFAVIRENZ; ERYTHROMYCIN; ESTROGEN; FLUCONAZOLE; FLUNITRAZEPAM; FLUVOXAMINE; FUSIDIC ACID; ITRACONAZOLE; JOSAMYCIN; KETOCONAZOLE; LOPINAVIR; METHADONE; MIBEFRADIL; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PAROXETINE; PHENOBARBITAL; SPIRAMYCIN; TROLEANDOMYCIN; UNINDEXED DRUG;

BURN; CANCER PAIN; CHRONIC PAIN; COMORBIDITY; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INTERACTION; DRUG METABOLISM; DRUG PROTEIN BINDING; ETHNICITY; GENDER; HEMATOCRIT; HUMAN; MENSTRUAL CYCLE; NEUROPATHIC PAIN; OBESITY; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; SENESCENCE; SEROTONIN SYNDROME;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; METHADONE; OROSOMUCOID;

SCOPUS;

EID: 80155189562     PISSN: 10408363     EISSN: 1549781X     Source Type: Journal    
DOI: 10.3109/10408363.2011.620601     Document Type: Review

References (236)

1. Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. J Am Med Assoc 1965;193:80-84.
2. Kreek MJ. Biological correlates of methadone maintenance pharmacotherapy. Ann Med Interne (Paris) 1994;145(Suppl 3):9-14. (Pubitemid 24380516)
3. Mizoguchi H, Watanabe C, Yonezawa A, Sakurada S. New therapy for neuropathic pain. Int Rev Neurobiol 2009;85:249-260.
4. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: A review. Pain 1993;52:137-147. (Pubitemid 23068182)
5. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997;70:109-115. (Pubitemid 27179621)
6. Kristensen K, Christensen CB, Christrup LL. The μ1, μ2, δ, κ opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995;56:PL45-PL50. (Pubitemid 24380184)
7. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade-a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians 1966;79:122-136.
8. Dole VP. Methadone treatment and the acquired immunodeficiency syndrome epidemic. JAMA 1989;262: 1681-1682.
9. Beswick T, Best D, Rees S, Coomber R, Gossop M, Strang J. Multiple drug use: Patterns and practices of heroin and crack use in a population of opiate addicts in treatment. Drug Alcohol Rev 2001;20:201-204.
10. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: A review. Mt Sinai J Med 2000;67:429-436.
11. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet 1996;30:385-401. (Pubitemid 26178257)
12. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006;41:563-572.
13. Schlatter J, Madras JL, Saulnier JL, Poujade F. Drug interactions with methadone. Presse Med 1999;28:1381-1384. (Pubitemid 29441080)
14. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291. (Pubitemid 28491214)
15. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002;41:1153-1193. (Pubitemid 35398691)
16. Sullivan HR, Smits SE, Due SL, Booher RE, McMahon RE. Metabolism of d-methadone: Isolation and identification of analgesically active metabolites. Life Sci 1972;11:1093-1104.
17. Sullivan HR, Due SL. Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 1973;16:909-913.
18. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 1985;233:1-6. (Pubitemid 15083518)
19. Nilsson MI, Widerlöv E, Meresaar U, Anggård E. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982;22:337-342.
20. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-373. (Pubitemid 26079977)
21. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-α-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997;25:1347-1353. (Pubitemid 28010919)
22. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-412. (Pubitemid 29161273)
23. Yue Q, Svensson JO, Bertilsson L, Sawe J. Racemic methadone kinetics in relation to the debrisoquine hydroxylation polymorphism in man. Abstracts of the 1st Congress of the European Association for Clinical Pharmacology and Therapeutics. Therapie 1995;88 (Suppl):27-30.
24. Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos 2003;31:742-747.
25. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004;16:36-44. (Pubitemid 37532283)
26. Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6-the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-137.
27. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007;321:389-399. (Pubitemid 46456979)
28. Wilkinson GR. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 1983;14:427-465. (Pubitemid 13077088)
29. Poulsen HE, Loft S. The impact of genetic polymorphisms in risk assessment of drugs. Arch Toxicol Suppl 1994;16:211-222.
30. Eap CB, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-234. (Pubitemid 32221062)
31. Perez de los CJ, Sinol N, Trujols J, del Rio E, Banuls E, Luquero E, Menoyo A, Queralto JM, Baiget M, Alvarez E. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007;89:190-194. (Pubitemid 46754669)
32. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505. (Pubitemid 30032252)
33. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drugmetabolizing enzymes in adults: A review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216. (Pubitemid 30242736)
34. Crettol S, Déglon JJ, Besson J Croquette-Krokkar M, Gothuey I, Hämmig R, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604. (Pubitemid 41773635)
35. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993;35:30-34. (Pubitemid 23016955)
36. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Arch Intern Med 2006;166:1280-1287. (Pubitemid 43967579)
37. Feely J, Grimm T. A comparison of drug protein binding and α 1-acid glycoprotein concentration in Chinese and Caucasians. Br J Clin Pharmacol 1991;31:551-552.
38. Kishino S, Nomura A, Di ZS, Sugawara M, Iseki K, Kakinoki S, et al. α-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J Clin Pharmacol 1995;35:510-514.
39. Krauss E, Polnaszek CF, Scheeler DA, Halsall HB, Eckfeldt JH, Holtzman JL. Interaction between human serum albumin and α 1-acid glycoprotein in the binding of lidocaine to purified protein fractions and sera. J Pharmacol Exp Ther 1986;239:754-759. (Pubitemid 17225844)
40. Szallasi A, Lewin NE, Blumberg PM. Identification of α-1-acid glycoprotein (orosomucoid) as a major vanilloid binding protein in serum. J Pharmacol Exp Ther 1992;262:883-888.
41. Israili ZH, Dayton PG. Human α-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001;33:161-235. (Pubitemid 32703255)
42. Olsen GD. Methadone binding to human plasma proteins. Clin Pharmacol Ther 1973;14:338-343.
43. Owens SM, Mayersohn M, Woodworth JR. Phencyclidine blood protein binding: Influence of protein, pH and species. J Pharmacol Exp Ther 1983;226:656-660. (Pubitemid 13007709)
44. Chauvelot-Moachon L, Marquis O, Giroud JP. Modification of propranolol binding to α-1-acid glycoprotein by serum albumin. Biochem Pharmacol 1985;34:1591-1594. (Pubitemid 15025805)
45. Shin WG, Lee MG, Lee MH, Kim ND. Factors influencing the protein binding of vancomycin. Biopharm Drug Dispos 1991;12:637-646.
46. Parker RB, Williams CL, Laizure SC, Lima JJ. Factors affecting serum protein binding of cocaine in humans. J Pharmacol Exp Ther 1995;275:605-610. (Pubitemid 26023605)
47. Morin D, Simon N, Deprés-Brummer P, Lévi F, Tillement JP, Urien S. Melatonin high-affinity binding to α-1-acid glycoprotein in human serum. Pharmacology 1997;54:271-275. (Pubitemid 27326258)
48. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 1990;48:10-17. (Pubitemid 20236197)
49. Dayton PG, Israili ZH, Perel JM. Influence of binding on drug metabolism and distribution. Ann NY Acad Sci 1973;226:172-194.
50. Levy G. Effects of plasma protein binding of drugs on duration and intensity of pharmacological activity. J Pharm Sci 1976;65:1264-1265.
51. Pacifici GM, Viani A, Taddeucci-Brunelli G, Rizzo G, Carrai M, Schulz HU. Effects of development, aging, and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and α 1-acid glycoprotein: Implications for binding of drugs. Ther Drug Monit 1986;8:259-263. (Pubitemid 16040532)
52. Meijer DK, Van der Sluijs P. The influence of binding to albumin and α 1-acid glycoprotein on the clearance of drugs by the liver. Pharm Weekbl Sci 1987;9:65-74. (Pubitemid 17046700)
53. Romach MK, Piafsky KM, Abel JG, Khouw V, Sellers EM. Methadone binding to orosomucoid (α 1-acid glycoprotein): Determinant of free fraction in plasma. Clin Pharmacol Ther 1981;29:211-217. (Pubitemid 11139898)
54. Wilkins JN, Ashofteh A, Setoda D, Wheatley WS, Huigen H, Ling W. Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. Ther Drug Monit 1997;19:83-87. (Pubitemid 28069001)
55. Garrido MJ, Aguirre C, Trocóniz IF, Marot M, Valle M, Zamacona MK, et al. α 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. Int J Clin Pharmacol Ther 2000;38:35-40. (Pubitemid 30048659)
56. Pos O, Moshage HJ, Yap SH, Snieders JP, Aarden LA, van Gool J, et al. Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of α 1-acid glycoprotein: Studies with primary human hepatocyte cultures and rats. Inflammation 1989;13:415-427. (Pubitemid 19188490)
57. Eap CB, Cuendet C, Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: Role of the variants of α 1-acid glycoprotein. Clin Pharmacol Ther 1990;47:338-346. (Pubitemid 20115020)
58. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004;25:423-429. (Pubitemid 38981558)
59. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80:682-690. (Pubitemid 44920224)
60. Levran O, O'Hara K, Peles E, Barral S, Ray B, Borg L, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-2227. (Pubitemid 351916578)
61. Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004;57:600-610. (Pubitemid 38582180)
62. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/indinavir. Anesthesiology 2009;110:660-672.
63. Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins GD, Ahmed MS. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005;69:1869-1878. (Pubitemid 40780085)
64. Yuferov V, Levran O, Proudnikov D, Nielsen DA, Kreek MJ. Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann NY Acad Sci 2010;1187:184-207.
65. Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001;23:553-555. (Pubitemid 32912279)
66. Sellers E, Lam R, McDowell J, Corrigan B, Hedayetullah N, Somer G, Kirby L, Kersey K, Yuen G. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following co-administration: CNAA1012. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 1999;39:25(abstract no. 663).
67. Rainey PM, Friedland G, McCance-Katz EF, Andrews L, Mitchell SM, Charles C, et al. Interaction of methadone with didanosine and stavudine. J Acquir Immune Defic Syndr 2000;24:241-248.
68. Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz EF. Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. Int Conf AIDS 2002;14(abstract no. TuPeB4548).
69. Smith PF, Kearney BP, Liaw S et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. Pharmacotherapy 2004;24:970-977. (Pubitemid 39025196)
70. Lüthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 2007;26:367-369. (Pubitemid 46716800)
71. Rainey PM, Friedland GH, Snidow JW, McCance-Katz EF, Mitchell SM, Andrews L, et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am J Addict 2002;11:66-74. (Pubitemid 34193880)
72. Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 1996;40:1514-1519. (Pubitemid 26169059)
73. Schwartz EL, Brechbühl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr 1992;5:619-626.
74. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:435-443.
75. Cretton-Scott E, de Sousa G, Nicholas F, Rahmani R, Sommadossi J-P. Methadone and its metabolite, N-demethyl methadone inhibits AZT glucuronidation in vitro. Clin Pharmacol Ther 1996;59:168.
76. McCance-Katz EF, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, et al. Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and delavirdine. Am J Addict 2006;15:23-34. (Pubitemid 43207186)
77. Booker B, Smith P, Forrest A, Difranscesco R, Morse G, Cottone P, Murphy M, McCance-Katz E. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & N-delavirdine (NDLV). Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother 2001;41(abstract no. A-490).
78. McCance-Katz EF, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M et al. Drug interactions between opioids and antiretroviral medications: Interaction between methadone, LAAM, and nelfinavir. Am J Addict 2004;13:163-180. (Pubitemid 38585697)
79. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. AIDS 2000;14:1291-1292. (Pubitemid 30420682)
80. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001;51:213-217. (Pubitemid 32391497)
81. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147-169. (Pubitemid 29101279)
82. Seminari E, Castagna A, Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 2008;6:427-433.
83. Schöller-Gyüre M, van den Brink W, Kakuda TN, Woodfall B, De Smedt G, Vanaken H et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008;48:322-329. (Pubitemid 351257768)
84. Otero MJ, Fuertes A, Sánchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: An alert. AIDS 1999;13:1004-1005. (Pubitemid 29240204)
85. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999;13:957-962. (Pubitemid 29240191)
86. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Dis 2001;33:1595-1597. (Pubitemid 34246157)
87. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 1999;19:471-472. (Pubitemid 29160164)
88. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz. Ann Pharmacother 2000;34:405-407. (Pubitemid 30133611)
89. Stocker H, Kruse G, Kreckel P, Herzmann C, Arastéh K, Claus J, et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48:4148-4153. (Pubitemid 39434868)
90. Hendrix CW, Wakeford J, Wire, Lou Y, Bigelow GE, Martinez E et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioiddependent subjects. Pharmacotherapy 2004;24:1110-1121. (Pubitemid 39128835)
91. Wire MB, Shelton MJ, Studenberg S. Fosamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006;45:137-168. (Pubitemid 43290828)
92. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-807. (Pubitemid 28319408)
93. Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavirritonavir in opioid-dependent subjects. Pharmacotherapy 2008;28:863-874. (Pubitemid 351875165)
94. Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005;19:1635-1641. (Pubitemid 41502676)
95. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998;26:257-260. (Pubitemid 28182402)
96. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C, Deutsch P. Lack of a pharmacokinetic interaction between indinavir and methadone. Clin Pharmacol Ther 1999:65;135(abstract no. PI-74).
97. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002;34:1143-1145. (Pubitemid 34289689)
98. McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 2003;37:476-482. (Pubitemid 37011769)
99. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A. Decrease in methodone levels with nelfinavir mesylate. Am J Psychiatry 2000;157:481. (Pubitemid 30145942)
100. Hsyu PH, Lillibridge J, Daniels E, Kerr BM. Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos 2006;27:61-68.
101. Marco A, Deig E, Cadafalch J, Fuster M, Valls I, Pedrol E. Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study). Med Clin (Barc) 2006;127:47-50.
102. Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009;101:158-168.
103. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D et al. ACTG 401 Study Team. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 2001;27:153-160. (Pubitemid 32595166)
104. Stevens RC, Rapaport S, Maroldo-Connelly L, Patterson JB, Bertz R. Lack of methadone dose alterations or withdrawal symptoms during therapy with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2003;33:650-651. (Pubitemid 36975855)
105. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy 2000;20:93-94. (Pubitemid 30036107)
106. Falconer M, Molloy D, Ingerhaug J, Barry M. Methadone induced torsade de pointes in a patient receiving antiretroviral therapy. Ir Med J 2007;100:631-632.
107. Shelton MJ, Cloen D, DiFrancesco R, Berenson CS, Esch A, de Caprariis PJ et al. The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol 2004;44:293-304. (Pubitemid 38233826)
108. Herrlin K, Segerdahl M, Gustafsson LL, Kalso E. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000;356:2069-2070. (Pubitemid 32009827)
109. Lee J, Franz L, Goforth HW. Serotonin syndrome in a chronicpain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine. Psychosomatics 2009;50:638-639.
110. Nair MK, Patel K, Starer PJ. Ciprofloxacin-induced torsades de pointes in a methadone-dependent patient. Addiction 2008;103:2062-2064.
111. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998;63:655-662. (Pubitemid 28327893)
112. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: Respiratory depression by drug interaction. J Pain Symptom Manage 2002;23:148-153. (Pubitemid 34158647)
113. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999;141 (Suppl 56):26-32.
114. Brockmeyer NH, Mertins L, Goos M. Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients. Klin Wochenschr 1991;69:16-18.
115. Reimann G, Barthel B, Rockstroh JK, Spatz D, Brockmeyer NH. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999;37:562-566. (Pubitemid 29524974)
116. Spatz D, Brockmeyer NH, Tillmann I, Mertins L, Goos M. Effect of fusidic acid on antipyrine pharmacokinetic parameters. Brit J Clin Pharmacol 1993;35:545.
117. NoorZurani MH, Vicknasingam B, Narayanan S. Itraconazoleinduced torsade de pointes in a patient receiving methadone substitution therapy. Drug Alcohol Rev 2009;28:688-690.
118. Flockhart DA. Drug Interactions: Cytochrom P450 Drug Interaction Table. Indiana University School of Medicine. Available at http://medicine.iupui.edu/ clinpharm/ddis/table. aspx. Accessed on 26 September 2011.
119. Morita K, Konishi H, Shimakawa H. Fluconazole: A potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole. Chem Pharm Bull 1992;40:1247-1251.
120. Komori T, Kai H, Shimoishi K, Kabu K, Nonaka A, Maruyama T et al. Up-regulation by clarithromycin of α(1)-acid glycoprotein expression in liver and primary cultured hepatocytes. Biochem Pharmacol 2001;62:1391-1397. (Pubitemid 33044685)
121. Oda Y, Kharasch ED. Metabolism of methadone and levo-α- acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): Potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001;298:1021-1032. (Pubitemid 32761918)
122. Brown LS, Sawyer RC, Li R, Cobb MN, Colborn DC, Narang PK. Lack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug users. Drug Alcohol Depend 1996;43:71-77. (Pubitemid 26382201)
123. Maurel P. The CYP 3A family. In: Ioannides C, ed. Cytochrome P450: Metabolic and Toxicological Aspects. Boca Raton, FL: CRC Press, 1996;196:241-270.
124. Benedetti MS. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol Res 1995;32:177-187. (Pubitemid 26072338)
125. Kreek MJ, Gutjahr CL, Garfield JW, Bowen DV, Field FH. Drug interactions with methadone. Ann NY Acad Sci 1976;281:350-371.
126. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. N Engl J Med 1976;294:1104-1106.
127. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 2007;51:110-118. (Pubitemid 46047695)
128. Gupta JD, Gruca M, Ablett W. Effect of other drugs and chemicals on the degradation of aspirin in vitro: Possible extrapolation to in vivo metabolism of aspirin. Eur J Drug Metab Pharmacokinet 1979;4:103-108. (Pubitemid 9223236)
129. Todd PA, Sorkin EM. Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1988;35:244-285.
130. Bianchi M, Clavenna A, Groff L, Zecca E, Ripamonti C. Diclofenac does not modify methadone bioavailability in cancer patients. J Pain Symptom Manage 1999;17:227-229.
131. Carlos MA, Du Souich P, Carlos R, Suarez E, Lukas JC, Calvo R. Effect of omeprazole on oral and intravenous RS-methadone pharmacokinetics and pharmacodynamics in the rat. J Pharm Sci 2002;91:1627-1638. (Pubitemid 34680225)
132. de Castro J, Aguirre C, Rodríguez-Sasiaín JM, Gómez E, Garrido MJ, Calvo R. The effect of changes in gastric pH induced by omeprazole on the absorption and respiratory depression of methadone. Biopharm Drug Dispos 1996;17:551-563. (Pubitemid 26319894)
133. Saxon AJ, Whittaker S, Hawker CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: Two cases. J Clin Psychiatry 1989;50:228-229. (Pubitemid 19198507)
134. Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr 1989;95:316-317. (Pubitemid 20347216)
135. Bell J, Seres V, Bowron P, Lewis J, Batey R. The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther 1988;43:623-629.
136. Tong TG, Pond SM, Kreek MJ, Jaffery NF, Benowitz NL. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981;94:349-351. (Pubitemid 11137077)
137. Bourgeois BF. Pharmacologic interactions between valproate and other drugs. Am J Med 1988;84:29-33.
138. Liu SJ, Wang RI. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am J Psychiatry 1984;141:1287-1288. (Pubitemid 14011518)
139. Liu SJ, Evans DB, Wang RI. Analysis and differentiation of mechanism of tolerance to methadone in methadone-fed rats. Biochem Pharmacol 1979;28:287-293. (Pubitemid 9083104)
140. Liu SJ, Evans DB, Wang RI. Correlation of urinary excretion of methadone metabolites with methadone metabolism and analgesia in the rat. J Pharmacol Exp Ther 1978;204:67-76. (Pubitemid 8269503)
141. Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 1998;35:405-423. (Pubitemid 29010173)
142. Iribarne C, Dréano Y, Bardou LG, Ménez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 1997;117:13-23. (Pubitemid 27063996)
143. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: Application in the management of cancer pain. Pain 1988;33:313-322.
144. Preston KL, Griffiths RR, Cone EJ, Darwin WD, Gorodetzky CW. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend 1986;18:195-202. (Pubitemid 16002934)
145. Pond SM, Tong TG, Benowitz NL, Jacob P 3rd, Rigod J. Lack of effect of diazepam on methadone metabolism in methadonemaintained addicts. Clin Pharmacol Ther 1982;31:139-143. (Pubitemid 12149378)
146. Shah NS, Patel VO, Donald AG. Effect of diazepam, desmethylimipramine, and SKF 525-A on the disposition of levomethadone in mice after single or double injection. Drug Metab Dispos 1979;7:241-242. (Pubitemid 10241182)
147. Spaulding TC, Minium L, Kotake AN, Takemori AE. The effect of diazepam on the metabolism of methadone by the liver of methadone-dependent rats. Drug Metab Dispos 1974;2:458-463.
148. Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. Am J Addict 2010;19:59-72.
149. Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend 2007;91:187-194. (Pubitemid 47554601)
150. Rapeli P, Fabritius C, Kalska H, Alho H. Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: Longitudinal change in comparison to healthy individuals. Subst Abuse Treat Prev Policy 2009;4:6.
151. Lintzeris N, Mitchell TB, Bond A, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006;26:274-283. (Pubitemid 43804619)
152. White JM, Irvine RJ. Future directions in opioid overdose. Addiction 1999;94:978-980.
153. Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M. Characteristics of
154. Farré M, Terán MT, Roset PN, Mas M, Torrens M, Camí J. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology (Berl) 1998;140:486-495. (Pubitemid 28566848)
155. Farré M, Terán MT, Camí J. A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. Psychopharmacology (Berl) 1996;125:1-12. (Pubitemid 26156632)
156. Borron SW, Monier C, Risède P, Baud FJ. Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 2002;21:599-605. (Pubitemid 36040802)
157. Baumann P, Tinguely D, Schöpf J. Increase of α 1-acid glycoprotein after treatment with amitriptyline. Br J Clin Pharmacol 1982;14:102-103. (Pubitemid 13147522)
158. Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry 1989;146:1611-1613. (Pubitemid 20014734)
159. Kosten TR, Gawin FH, Morgan C, Nelson JC, Jatlow P. Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. Am J Drug Alcohol Abuse 1990;16:329-336.
160. Eich-Höchli D, Oppliger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John's Wort-a case report. Pharmacopsychiatry 2003;36:35-37.
161. Izzo AA. Drug interactions with St. John's Wort (Hypericum perforatum): A review of the clinical evidence. Int J Clin Pharmacol Ther 2004;42:139-148. (Pubitemid 38647590)
162. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-45. (Pubitemid 24042311)
163. Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997;17:113-117. (Pubitemid 27148308)
164. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214. (Pubitemid 23098317)
165. Iribarne C, Picart D, Dréano Y, Berthou F. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 1998;12:194-199. (Pubitemid 28154609)
166. DeMaria PA Jr, Patkar AA, Vassos K. Fluvoxamine as an adjunct to promote methadone dose optimization. Addict Disord Treatment 2003;2:85-89. (Pubitemid 37087390)
167. Bertschy G, Eap CB, Powell K, Baumann P. Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. Ther Drug Monit 1996;18:570-572. (Pubitemid 26330478)
168. Begré S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002;22:211-215. (Pubitemid 34289398)
169. Hamilton SP, Nunes EV, Janal M, Weber L. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000;9:63-69. (Pubitemid 30155034)
170. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265.
171. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM et al. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl) 1996;128:398-407. (Pubitemid 26417681)
172. Martinez TT, Martinez DN. A case of serotonin syndrome associated with methadone overdose. Proc West Pharmacol Soc 2008;51:42-44.
173. Baño MD, Micó JA, Agujetas M, López ML, Guillén JL. Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels. Actas Esp Psiquiatr 2001;29:215-220. (Pubitemid 33673385)
174. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007;27:273-278. (Pubitemid 46763309)
175. Sorkin EM, Ogawa GS. Cimetidine potentiation of narcotic action. Drug Intell Clin Pharm 1983;17:60-61. (Pubitemid 13217344)
176. Dawson GW, Vestal RE. Cimetidine inhibits the in vitro N-demethylation of methadone. Res Commun Chem Pathol Pharmacol 1984;46:301-304. (Pubitemid 15191353)
177. Hunter J, Chasseaud LF. Clinical aspects of microsomal enzyme induction. In: Bridges JW, Chasseaud LF, eds. Progress in Drug Metabolism, Vol. 1. New York: Wiley, 1976: 129-191.
178. Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003;31:768-772. (Pubitemid 36617666)
179. Iribarne C, Picart D, Dréano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997;60:1953-1964. (Pubitemid 27224184)
180. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.
181. Lotrich FE, Rosen J, Pollock BG. Dextromethorphan-induced delirium and possible methadone interaction. Am J Geriatr Pharmacother 2005;3:17-20. (Pubitemid 41122354)
182. Cornish JW, Herman BH, Ehrman RN, Robbins SJ, Childress AR, Bead V et al. A randomized, double-blind, placebocontrolled safety study of high-dose dextromethorphan in methadone-maintained male inpatients. Drug Alcohol Depend 2002;67:177-183. (Pubitemid 34722405)
183. Mannelli P, De Risio S, Pozzi G, Janiri L, De Giacomo M. Serendipitous rapid detoxification from opiates: The importance of time-dependent processes. Addiction 1999;94:589-591. (Pubitemid 29179129)
184. Kreek MJ. Metabolic interactions between opiates and alcohol. Ann NY Acad Sci 1981;362:36-49. (Pubitemid 11000880)
185. Cushman P, Kreek MJ, Gordis E. Ethanol and methadone in man: A possible drug interaction. Drug Alcohol Depend 1977;3:35-42. (Pubitemid 8223869)
186. Mayer JM. Mechanisms of drug interactions with alcohol. Adv Alcohol Subst Abuse 1984;3:7-19. (Pubitemid 14026648)
187. Clark NC, Dietze P, Lenné MG, Redman JR. Effect of opioid substitution therapy on alcohol metabolism. J Subst Abuse Treat 2006;30:191-196.
188. Tong TG, Benowitz NL, Kreek MJ. Methadone-disulfiram interaction during methadone maintenance. J Clin Pharmacol 1980;20:506-513.
189. Charuvastra CV, Panell J, Hopper M, Erhmann M, Blakis M, Ling W. The medical safety of the combined usage of disulfiram and methadone. Pharmacological treatment for alcoholic heroin addicts. Arch Gen Psychiatry 1976;33:391-393.
190. Hallinan R, Crettol S, Agho K, Attia J, Besson J, Croquette-Krokar M et al. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: A transnational study. Eur J Clin Pharmacol 2009;65:1113-1120.
191. McCance-Katz EF, Jatlow P, Rainey PM. Effect of cocaine use on methadone pharmacokinetics in humans. Am J Addict 2010;19:47-52.
192. Hsu WY, Chiu NY, Liao YC. Rhabdomyolysis and brain ischemic stroke in a heroin-dependent male under methadone maintenance therapy. Acta Psychiatr Scand 2009;120:76-79.
193. Elkader AK, Brands B, Selby P, Sproule BA. Methadone-nicotine interactions in methadone maintenance treatment patients. J Clin Psychopharmacol 2009;29:231-238.
194. Spiga R, Schmitz J, Day J 2nd. Effects of nicotine on methadone self-administration in humans. Drug Alcohol Depend 1998;50:157-165. (Pubitemid 28271630)
195. Benmebarek M, Devaud C, Gex-Fabry M, Powell Golay K, Brogli C, Baumann P et al. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther 2004;76:55-63. (Pubitemid 38844734)
196. Schroeder JR, Schmittner J, Bleiberg J, Epstein DH, Krantz MJ, Preston KL. Hemodynamic and cognitive effects of lofexidine and methadone coadministration: A pilot study. Pharmacotherapy 2007;27:1111-1119. (Pubitemid 47173657)
197. Sulkowski M, Wright T, Rossi S, Arora S, Lamb M, Wang K et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. Clin Pharmacol Ther 2005;77:214-224. (Pubitemid 40269136)
198. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003;98:2281-2288. (Pubitemid 37305371)
199. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37:443-451. (Pubitemid 36152544)
200. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120-124. (Pubitemid 38868930)
201. Symonds P. Methadone and the elderly. Br Med J 1977;1:512. (Pubitemid 8024200)
202. Tuttle CB. Drug management of pain in cancer patients. Can Med Assoc J 1985;132:121-134. (Pubitemid 15197261)
203. Wood M, Wood AJ. Changes in plasma drug binding and α 1-acid glycoprotein in mother and newborn infant. Clin Pharmacol Ther 1981;29:522-526. (Pubitemid 11039807)
204. Liu AJ, Jones MP, Murray H, Cook CM, Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. Aust NZ J Obstet Gynaecol 2010;50:253-258.
205. Fabris C, Prandi G, Perathoner C, Soldi A. Neonatal drug addiction. Panminerva Med 1998;40:239-243. (Pubitemid 128523719)
206. Veering BT, Burm AG, Souverijn JH, Serree JM, Spierdijk J. The effect of age on serum concentrations of albumin and α 1-acid glycoprotein. Br J Clin Pharmacol 1990;29:201-206. (Pubitemid 20131418)
207. Johnson JA, Livingston TN. Differences between blacks and whites in plasma protein binding of drugs. Eur J Clin Pharmacol 1997;51:485-488. (Pubitemid 27317787)
208. Kishino S, Nomura A, Itoh, Nakagawa T, Takekuma Y, Sugawara M et al. Age-and gender-related differences in carbohydrate concentrations of α1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities. Eur J Clin Pharmacol 2002;58:621-628. (Pubitemid 35478189)
209. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JG, van Wilgenburg H. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995;48:361-366.
210. Parish RC, Spivey C. Influence of menstrual cycle phase on serum concentrations of α 1-acid glycoprotein. Br J Clin Pharmacol 1991;31:197-199.
211. Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA. Methadone: A substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos 2010;38:1308-1313.
212. Benedek IH, Fiske WD 3rd, Griffen WO, Bell RM, Blouin RA, McNamara PJ. Serum α 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 1983;16:751-754. (Pubitemid 14208224)
213. Benedek IH, Blouin RA, McNamara PJ. Serum protein binding and the role of increased α 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984;18:941-946. (Pubitemid 15190533)
214. Routledge PA, Shand DG, Barchowsky A, Wagner G, Stargel WW. Relationship between α 1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther 1981;30:154-157. (Pubitemid 11039350)
215. Jackson PR, Tucker GT, Woods HF. Altered plasma drug binding in cancer: Role of α 1-acid glycoprotein and albumin. Clin Pharmacol Ther 1982;32:295-302. (Pubitemid 13097364)
216. Piafsky KM, Borgá O, Odar-Cederlöf I, Johansson C, Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma α1 acid glycoprotein. N Engl J Med 1978;299:1435-1439. (Pubitemid 9192306)
217. Jarvis MA, Wu-Pong S, Kniseley JS, Schnoll SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999;18:51-61. (Pubitemid 30053427)
218. Wolff K, Boys A, Rostami-Hodjegan A, Hay A, Raistrick D. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005;61:763-768. (Pubitemid 41674263)
219. Nanovskaya TN, Deshmukh SV, Nekhayeva IA, Zharikova OL, Hankins GD, Ahmed MS. Methadone metabolism by human placenta. Biochem Pharmacol 2004;68:583-591. (Pubitemid 38887440)
220. Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005;192:633-639.
221. Hieronymus TL, Nanovskaya TN, Deshmukh SV, Vargas R, Hankins GD, Ahmed MS. Methadone metabolism by early gestational age placentas. Am J Perinatol 2006;23:287-294.
222. Szeto HH, Umans JG, McFarland J. A comparison of morphine and methadone disposition in the maternal-fetal unit. Am J Obstet Gynecol 1982;143:700-706. (Pubitemid 12082165)
223. Szeto HH, Clapp JF 3rd, Larrow RW, Hewitt J, Inturrisi CE, Mann LI. Disposition of methadone in the ovine maternal-fetal unit. Life Sci 1981;28:2111-2117. (Pubitemid 11089604)
224. Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006;15:258-259.
225. Bellward GD, Warren PM, Howald W, Axelson JE, Abbott FS. Methadone maintenance: Effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther 1977;22:92-99. (Pubitemid 8155117)
226. Baselt RC, Casarett LJ. Urinary excretion of methadone in man. Clin Pharmacol Ther 1972;13:64-70.
227. Bonate PL. Pathophysiology and pharmacokinetics following burn injury. Clin Pharmacokinet 1990;18:118-130. (Pubitemid 20104031)
228. Denson DD, Concilus RR, Warden G, Raj PP. Pharmacokinetics of continuous intravenous infusion of methadone in the early postburn period. J Clin Pharmacol 1990;30:70-75. (Pubitemid 20072728)
229. Novick DM, Kreek MJ, Fanizza AM, Yancovitz SR, Gelb AM, Stenger RJ. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981;30:353-362. (Pubitemid 11061959)
230. Kreek MJ, Bencsath FA, Fanizza A, Field FH. Effects of liver disease on fecal excretion of methadone and its unconjugated metabolites in maintenance patients. Quantitation by direct probe chemical ionization mass spectrometry. Biomed Mass Spectrom 1983;10:544-549. (Pubitemid 14187927)
231. Abramson FP. Methadone plasma protein binding: Alterations in cancer and displacement from α 1-acid glycoprotein. Clin Pharmacol Ther 1982;32:652-658. (Pubitemid 13096711)
232. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002;41:1135-1151. (Pubitemid 35398690)
233. Tuchschmidt J, Oblitas D, Fried JC. Oxygen consumption in sepsis and septic shock. Crit Care Med 1991;19:664-671.
234. Liu LU, Schiano TD, Lau N, Rourke M, Min AD, Sigal SH, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant 2003;3:1273-1277. (Pubitemid 37214624)
235. Weinrieb RM, Barnett R, Lynch KG, DePiano M, Atanda A, Olthoff KM. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004;10:97-106. (Pubitemid 38885900)
236. Venkataramanan R, Habucky K, Burckart GJ, Ptachcinski RJ. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989;16:134-161. (Pubitemid 19097615)